Stockscreener 앱 받기
155.41
0.19%
0.29
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - Ad-hoc-news.de
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - Ad-hoc-news.de
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - Ad-hoc-news.de
Novartis strategy highlighted by remibrutinib and Sandoz spin-off, shares steady on SIX - Ad-hoc-news.de
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years - The Motley Fool
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - Ad-hoc-news.de
NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart - ChartMill
Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG Stock (CH0012005267): Earnings in focus for US investors - Ad-hoc-news.de
Novartis AG Stock (CH0012005267): Analyst Targets and SMI Role Keep Shares in Focus - Ad-hoc-news.de
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Sahm
Novartis AG Stock (NVS) Moved Down by 3.14% on Jun 1: Key Drivers Unveiled - TradingKey
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - Ad-hoc-news.de
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - Ad-hoc-news.de
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
Novartis stock (CH0012005267): FDA progress and market focus - Ad-hoc-news.de
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
1.47%
자본화:
|
볼륨(24시간):